INDUSTRIEPARK ZWIJNAARDE 7, ZWIJNAARDE, C9
Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Reports First Quarter 2026 Financial Results and Provides Business Update
Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer
Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
Announces Annual General Meeting of Shareholders on May 6, 2026
2025 Annual Report including the Annual Financial Statements for the year ended December 31, 2025
To Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
Annual and Transition Report of Foreign Private Issuers
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
No filings found
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Free Writing Prospectus
Confidential Treatment Order
Registration Statement for Additional Securities of Certain Foreign Private Issuers, Filed Pursuant to Rule 462(b)